Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sleep Extension Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Social Determinants of Sleep and Obesity

NCT05698693
View directory record Official record
Conditions
Insufficient Sleep, Physical Inactivity, Sedentary Behavior, Obesity
Interventions
Sleep intervention, Contact Control
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 22, 2026, 6:49 AM EDT
Not listed Phase 4 Interventional

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02560766
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg, HORIZANT 600 mg, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

NCT03001557
View directory record Official record
Conditions
Irregular Sleep-Wake Rhythm Disorder
Interventions
Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 22, 2026, 6:49 AM EDT
Completed No phase listed Observational

Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopnea

NCT00849043
View directory record Official record
Conditions
Obstructive Sleep Apnea Hypopnea, Obstructive Sleep Apnea, OSAH
Interventions
Not listed
Lead sponsor
Ventus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Wallingford, Connecticut • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 22, 2026, 6:49 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Sleep Extension in Adolescents

NCT03500458
View directory record Official record
Conditions
Insulin Sensitivity, Sleep, Dietary Habits
Interventions
Sleep Extension
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 19 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo

NCT00283790
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Not applicable Interventional Results available

Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes

NCT03398902
View directory record Official record
Conditions
PreDiabetes
Interventions
Sleep extension, Habitual sleep
Behavioral · Other
Lead sponsor
New York University
Other
Eligibility
21 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

NCT02720744
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 22, 2026, 6:49 AM EDT
Recruiting Phase 4 Interventional

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

NCT06751992
View directory record Official record
Conditions
Kidney Transplant Recipients, Old Age
Interventions
Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Active, not recruiting Phase 2 Interventional

Terazosin and Parkinson's Disease Extension Study

NCT05109364
View directory record Official record
Conditions
Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Interventions
Terazosin therapy
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiovascular Risk and Circadian Misalignment in Short Sleepers - Role of Extended Eating Period

NCT06070194
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

NCT01429116
View directory record Official record
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Sleep Extension to Improve Sleep Efficiency and QoL in HF With Preserved Ejection Fraction: the SLEEP-HF Pilot Study

NCT06567925
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Customized Sleep Coaching, Sleep Hygiene Training
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Duration in Women With Previous Gestational Diabetes

NCT03638102
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Sleep extension, Healthy living
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Teen Sleep Health Study

NCT04087603
View directory record Official record
Conditions
Sleep Disorders, Circadian Rhythm, Adolescent Behavior
Interventions
Weekend Morning Bright Light & Early Bedtime
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
14 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 22, 2026, 6:49 AM EDT
Withdrawn Not applicable Interventional

A Sleep Extension Pilot Study in Adults With Obesity

NCT05747105
View directory record Official record
Conditions
Obesity, Sleep, Weight, Body, Eating Behavior, Blood Pressure, Quality of Life
Interventions
Sleep Extension
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 22, 2026, 6:49 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Jul 22, 2026, 6:49 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06767683
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Completed Not applicable Interventional Results available

Sleep Extension or Regularity to Reduce Diabetes Risk

NCT06128265
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Sleep Extension, Sleep Regularity
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 6:49 AM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 22, 2026, 6:49 AM EDT